- Company
- Tecentriq, first immunotherapy reimbursed in liver cancer
- by jung, sae-im Apr 22, 2022 06:07am
- Roche’s Tecentriq(atezolizumab) became the first cancer immunotherapy to be approved for reimbursement in liver cancer. Analysts have assessed that it had prepared the footsold to expand its sales with the first expansion in its scope of reimbursement in 3 years since 2019. Tecentriq is continuing its stride to overcome the stronghold of Ke
- Company
- The opinions of the pharmaceutical community vary widely
- by jung, sae-im Apr 22, 2022 06:07am
- Employees of pharmaceutical companies who have entered the era of post-COVID-19 due to the end of social distancing are divided. Various opinions are coming out as it is divided into pharmaceutical companies that maintain telecommuting and pharmaceutical companies that terminate. Pros and cons also followed group meetings such as company dinn
- InterView
- We are making all efforts to reimburse ‘Vyndamax’
- by Eo, Yun-Ho Apr 21, 2022 06:03am
- Rare disease patients suffer more due to the 'rarity' of their condition. Due to the small number of affected patients, even drugs that are already available cannot be easily listed for reimbursement due to difficulty in demonstrating cost-effectiveness or predicting their fiscal impact on the NHI budget. Rare diseases are diseases that
- Opinion
- [Reporter’s View] 1st oral abortion pill approval difficult
- by Lee, Hye-Kyung Apr 21, 2022 06:03am
- A year has passed since the decriminalization of the abortion ban has taken effect. The Korean Health and Medical Workers’ Union distributed a press release on the 11th on ‘ensuring safe abortion of the people 1 year after the decriminalization of abortion in Korea.’ The press release contained the request for marketing authorization o
- Company
- Companies are struggling with the form of post-COVID-19 work
- by Apr 20, 2022 06:06am
- As social distancing measures are lifted in two years, changes are also detected in the pharmaceutical industry. However, telecommuting is unlikely to disappear immediately. As more and more conferences attempt online and offline hybridization this year, they are also cautious about overseas business trips. ◆ Maintaining voluntary work
- Opinion
- [Reporter’s View] Patience is a virtue...for drugs?
- by Eo, Yun-Ho Apr 20, 2022 06:05am
- Price falls when supply increases. The same goes for the pharmaceutical market. Although the government can reduce fiscal spending by inducing competition between pharmaceutical companies, this would lead to a delay in NHI reimbursement listing. As we enter the era of high-priced drugs, the government has been exercising the ‘art of
- Company
- Homegrown Rosuzet·K-CAB sell over ₩10 bil a month
- by Chon, Seung-Hyun Apr 20, 2022 06:05am
- New drugs developed by Korean pharmaceutical companies are showing strength in the prescription market. Hanmi Pharmaceutical’s Rosuzet and HK Inno. N’s K-CAB has recorded over &8361;10 billion in monthly sales and made a good start. According to the market research institution UBIST on the 19th, the hyperlipidemia treatment Lipitor record
- Product
- The KPA establishes an emergency TFT
- by Apr 20, 2022 06:05am
- As the presidential transition committee is expected to include the permission of non-face-to-face medical treatment in its national agenda and fully review the revision of the law, the KPA has begun to come up with measures. The Chairman Choi Kwang-hoon formed a TFT related to non-face-to-face treatment and convened his first meeting toda
- Policy
- Expanding the use of Paxlovid with underlying dz over 12 yrs
- by Lee, Jeong-Hwan Apr 20, 2022 06:05am
- The government said it is considering expanding the scope of the prescription for Paxlovid, an oral treatment for COVID-19, to "underlying patients aged 12 or older." However, considering the fact that there are side effects, it is said that various decision-making processes such as collecting opinions from experts should be carried out. T
- Product
- Non-face-to-face tx companies are appealing for regulations
- by Jung, Heung-Jun Apr 20, 2022 06:05am
- Non-face-to-face treatment companies are appealing for regulatory improvement ahead of the abolition of social distancing and easing the level of infectious diseases. Pharmacists are protesting that the reason for non-face-to-face is disappearing and that they should take steps to temporarily terminate the permit as scheduled. According to th
